comparemela.com
  1. Home
  2. Live Updates
  3. Iris Loew Friedrich - Breaking News

Latest Breaking News On - Iris loew friedrich - Page 6 : comparemela.com

UCB : announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U S FDA and designated for Priority Review

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review Biologic License. | January 6, 2023

Bruxelles capitaleCharl van zylJim baxterIris loew friedrichAntje witteLaurent schotsBrand communicationsEu internationalEuropean commissionDrug administrationNeurology solutions headCorporate communicationsMyasthenia gravis foundation of americaEuropean medicines agencyLancet reg health west pacCommittee for medicinal products human use

FDA to Review Zilucoplan for Generalized Myasthenia Gravis

The FDA has accepted the NDA for zilucoplan for the treatment of generalized myasthenia gravis in adults who are AChR-Ab+.

Iris loew friedrichDrug administrationNew drug applicationMyasthenia gravis activitiesDaily livingQuantitative myasthenia gravisMyasthenia gravis compositeMyasthenia gravisExecutive vice presidentChief medical officer

UCB announces U S FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine.

United kingdomBruxelles capitaleGreat britainDaphne teoCharl van zylJim baxterIris loew friedrichNeuromuscul disordAntje witteLaurent schotsUs communicationsBrand communicationsEu internationalEuropean commissionDrug administrationNeurology solutions head

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

/PRNewswire/ UCB, a global biopharmaceutical company, announced today it is presenting results from across its portfolio in generalized myasthenia gravis.

Bruxelles capitaleDaphne teoCharl van zylJim baxterIris loew friedrichAntje witteLaurent schotsNeurology head of europe internationalUs communicationsAmerican association of neuromuscular electrodiagnostic medicineBrand communicationsEuropean commissionDrug administrationCorporate communicationsEuropean unionMyasthenia gravis foundation of america

FDA turns down UCB application for psoriasis treatment

UCB will review its full-year financial guidance in light of the agency's decision on its drug, bimekizumab.

United statesTiffany chanIris loew friedrichDrug administrationAmerican academy of dermatology summer meetingLicense applicationResponse letterDermatology summer meeting

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.